TTM
30.6%
YoY change
+5.69pp
Trough year (FY2006)
-2148.7%
Peak year (FY2025)
29.1%
Latest annual
29.1%
EBITDA Margin history chart for DexCom (DXCM) from 2016 to 2025
Latest: 29.1%
EBITDA Margin change chart for DexCom (DXCM) from 2016 to 2025
Latest: +5.69pp
EBITDA Margin history table for DexCom (DXCM) from 2006 to 2025
| FY2025 | 29.1% | +5.69pp | ||
| FY2024 | 23.4% | -1.86pp | ||
| FY2023 | 25.3% | +5.88pp | ||
| FY2022 | 19.4% | +4.01pp | ||
| FY2021 | 15.4% | -4.14pp | ||
| FY2020 | 19.6% | +5.11pp | ||
| FY2019 | 14.4% | +21.69pp | ||
| FY2018 | -7.2% | -4.50pp | ||
| FY2017 | -2.7% | +5.84pp | ||
| FY2016 | -8.6% | +2.94pp | ||
| FY2015 | -11.5% | -6.46pp | ||
| FY2014 | -5.1% | +8.63pp | ||
| FY2013 | -13.7% | +35.36pp | ||
| FY2012 | -49.0% | +4.68pp | ||
| FY2011 | -53.7% | +51.52pp | ||
| FY2010 | -105.3% | +39.92pp | ||
| FY2009 | -145.2% | +360.94pp | ||
| FY2008 | -506.1% | +430.65pp | ||
| FY2007 | -936.8% | +1211.92pp | ||
| FY2006 | -2148.7% | — |
- FY202529.1%+5.69pp
- FY202423.4%-1.86pp
- FY202325.3%+5.88pp
- FY202219.4%+4.01pp
- FY202115.4%-4.14pp
- FY202019.6%+5.11pp
- FY201914.4%+21.69pp
- FY2018-7.2%-4.50pp
- FY2017-2.7%+5.84pp
- FY2016-8.6%+2.94pp
- FY2015-11.5%-6.46pp
- FY2014-5.1%+8.63pp
- FY2013-13.7%+35.36pp
- FY2012-49.0%+4.68pp
- FY2011-53.7%+51.52pp
- FY2010-105.3%+39.92pp
- FY2009-145.2%+360.94pp
- FY2008-506.1%+430.65pp
- FY2007-936.8%+1211.92pp
- FY2006-2148.7%—
EBITDA Margin values are taken from DexCom's reported income statements (quarterly 10-Q and annual 10-K filings with the U.S. Securities and Exchange Commission). Each row shows the period end date and the filing date. YoY compares each figure to the same period one year earlier. Amounts are in USD as filed.
About EBITDA Margin at DexCom (DXCM)
According to DexCom's latest reported financial statements, the company's latest reported EBITDA margin is 30.6%. EBITDA margin is EBITDA divided by revenue — earnings before interest, taxes, depreciation, and amortization as a percentage of sales. By stripping out non-cash charges and capital-structure effects, it approximates operating cash profitability and is widely used to compare companies with different asset bases and leverage.
Headline figure above is from the reporting period ending (reported ). Chart and table below cover the full reported history back to .
DexCom (DXCM) most recent annual EBITDA margin stands at 29.14% (2025) – expanded 5.7 percentage points year-over-year.
Across the available history, EBITDA margin reached its high of 29.14% in 2025 and its low of -2148.69% in 2006.
DexCom EBITDA Margin by Year
DexCom EBITDA Margin 2025: 29.1%
In 2025, DexCom reported EBITDA margin of 29.14%, expanded 5.7 percentage points from 2024. This figure represents the highest annual value in the available history.
DexCom EBITDA Margin 2024: 23.4%
DexCom EBITDA margin in 2024 was 23.45%, contracted 1.9 percentage points from 2023.
DexCom EBITDA Margin 2023: 25.3%
2023's EBITDA margin for DexCom came in at 25.31%, expanded 5.9 percentage points from 2022.
DexCom EBITDA Margin 2022: 19.4%
DexCom posted EBITDA margin of 19.43% in 2022, expanded 4.0 percentage points from 2021.
DexCom EBITDA Margin 2021: 15.4%
DexCom EBITDA margin in 2021 was 15.42%.
See more financial history for DexCom (DXCM).
Sector peers by EBITDA Margin
Healthcare peers of DexCom (DXCM), ranked by their latest EBITDA margin
| 56.7% | |
| 46.3% | |
| 44.8% | |
| 32.6% | |
| 28.6% | |
| 26.9% | |
| 24.7% | |
| 5.7% |
- 56.7%
- 46.3%
- 44.8%
- 28.6%
- 26.9%
Frequently asked questions
DexCom (DXCM) Key Financials
Charts, filings, and peer comparison for every metric
Explore more
Deep-dives across the income statement, cash flow, capital return, and valuation
How this company returns cash to shareholders — buybacks, dividends, and stock splits.